REGN · Regeneron Pharmaceuticals, Inc.

The thesis

Regeneron's earnings have stepped up because it now collects its full share of Dupixent profits, and EYLEA HD and Libtayo add growth on top of that. The Q4 2026 report settles whether that profit level holds, and the FDA's November 2026 decision on cemdisiran tests the next launch.

The company reported on 30 October 2026. Revenue rose 36% to $5.116 billion. Investing.com reported that Q3 was the first full quarter after Regeneron finished repaying the Dupixent development balance, and Sanofi collaboration revenue hit a record $2.724 billion. With the repayment complete, the higher profit share should carry into later quarters. Q4 collaboration revenue below $2.724 billion, excluding the one-time $1.0 billion Sanofi upfront, would show that view is wrong.

The main change since the 3 November 2026 note is price and insider selling. The shares closed at $902.90 on 5 November 2026, down 7.2% from the $973.36 52-week high on adjusted daily closes. Four insiders reported sales at about $964 to $970 per share after the report (SEC Form 4 summaries). Company news from 3 November to 6 November 2026 shows no downgrade and no change to the business results.

The narrative is maturing: the Q3 beat is widely known, most brokers raised their targets by 3 November 2026, and the 14-day relative strength index (RSI) cooled to 68.2 on 5 November 2026 from 88.0 on 2 November 2026.

Bullish and bearish views on Regeneron Pharmaceuticals, Inc.

The bull case on Regeneron Pharmaceuticals, Inc. (REGN), in brief: The full Dupixent profit share is flowing. The bear case: Insiders sold into the high.

Bull case

• The full Dupixent profit share is flowing. Sanofi records Dupixent sales, which reached $6.541 billion worldwide in Q3 2026, up 35% (Regeneron 8-K, 30 October 2026). Q3 was the first full quarter after the development balance was repaid (Investing.com, 2 November 2026).
• EYLEA HD demand is still rising. U.S. Management guided to about 10% sequential demand growth in Q4.
• Libtayo has become a growth product. Worldwide Libtayo sales rose 51% to $550 million in Q3 2026 (8-K, 30 October 2026). Updated Phase 3 C-POST results at ESMO on 25 October 2026 showed a 37% lower risk of death than placebo in high-risk cutaneous squamous cell carcinoma, a type of skin cancer.
• Cemdisiran is the nearest new launch. The FDA is reviewing it for generalized myasthenia gravis under priority review, with a November 2026 target date. The Phase 3 NIMBLE trial showed a 2.3-point placebo-adjusted improvement on the 24-point daily-activities scale at 24 weeks, with dosing every 12 weeks (June 2026 filing-acceptance coverage).
• Target raises continued after the report. DZ Bank raised its target to $1,067 from $900 (company news, 5 November 2026). JPMorgan moved to $1,050 from $950 on 30 October 2026 (MarketBeat), and Leerink, rated Market Perform, went to $997 on 2 November 2026 (Benzinga). BofA Securities added the shares to its November "Value 10" list on 4 November 2026.
• The valuation and balance sheet leave room. MarketBeat showed a price-to-earnings ratio of 20.38 on 5 November 2026.
• The pipeline keeps moving. Intellia and Regeneron completed enrollment in the Phase 3 MAGNITUDE-2 trial of nex-z in hereditary transthyretin amyloidosis with nerve damage (company news, 4 November 2026). ClinicalTrials.gov lists a Phase 3 ALN-CIDEB trial in fatty liver disease with an estimated start of 6 November 2026.

Bear case

• Insiders sold into the high. Director George Sing sold 21,129 shares at $964.38, director Christine Poon sold 7,830 at $969.09, and general counsel Joseph LaRosa sold 4,466 at $965.49, all reported for 2 November 2026 (MarketBeat; Quantisnow's Form 4 summaries). These sales followed option exercises at strikes of $376.69 to $381.92, and Quantisnow labels other recent insider sales as pre-agreed trading-plan sales but not these four.
• Neutral analysts cluster around the price. Bernstein at $812, Morgan Stanley at $855 and Baird at $875 sit under the $902.90 close, while RBC Capital at $913 and Wells Fargo at $925 sit just above it (Benzinga, 2 November 2026). MarketBeat's consensus target was $898.97 on 5 November 2026.
• Q4 comparisons will flatter growth. The $1.0 billion Sanofi upfront is booked as Q4 2026 collaboration revenue (8-K, 30 October 2026). Headline Q4 revenue will therefore say little about the underlying profit share.
• Research spending is climbing. Management expects 2027 research and development expense to rise by a mid-teens percentage (Investing.com, 2 November 2026). That takes back part of the earnings step-up.
• The EYLEA HD syringe depends on outside manufacturers. The FDA rejected an earlier syringe filing in 2025 over inspection findings at Catalent (Benzinga). Management's goal is approval by the end of 2026 while it works with the FDA and third-party fillers (Q3 2026 coverage, Stockhub).
• Retina competition remains live. The shares fell on 29 April 2026 on weak total U.S. EYLEA sales and concern about competition in the retina market (MarketBeat). EYLEA HD growth has to outrun the decline in the older 2 mg product.

Price setup

The shares closed at $927.89 on the 30 October 2026 report day and $961.26 on 2 November 2026, then reached the $973.36 52-week high on adjusted daily closes. The $902.90 close on 5 November 2026 sits below the report-day close. MarketBeat lists a $991.73 intraday 52-week high and a $591.52 low.

The three-month gain was 11.9% at the 5 November 2026 close. RSI at 68.2 is no longer at the extreme 88.0 reading of 2 November 2026, so the pullback has eased the most obvious stretch in the price. It leaves the business case unchanged and keeps the shares above the $850 invalidation level.

Crowding evidence is visible. The close sits well above the 50-day moving average of $800.69 and the 200-day moving average of $741.11 (MarketBeat, 5 November 2026). CNBC's "Final Trades" named the shares on 2 November 2026 and 3 November 2026. Insider sales clustered after the report, and an FDA decision falls within the month. No earnings report falls in the next 30 days.

Catalysts, next 30 days

• 9 November 2026: The AASLD Liver Meeting in Denver ends; it was the expected venue for interim CIDEB results in fatty liver disease. No CIDEB readout had appeared in company news by 6 November 2026.
• 17 November 2026: Regeneron presents at the Jefferies Global Healthcare Conference in London at 9:00 a.m. ET (company release, 2 November 2026).
• 20 November 2026: Record date for the $0.94 quarterly dividend, payable 3 December 2026.
• ~30 November 2026, est.: FDA decision on cemdisiran for generalized myasthenia gravis. The target is November 2026; the company has given no exact day, and no decision had been reported by 6 November 2026.
• 1 December 2026 and 2 December 2026: Regeneron presents at the Evercore Healthcare Conference (1:45 p.m. ET) and Citi's Global Healthcare Conference (9:40 a.m. ET).

Later events the case turns on:

• ~31 December 2026, est.: FDA decision on the EYLEA HD prefilled syringe, which management targets by year-end.
• ~29 January 2027, est.: Q4 2026 results, the main test of the Sanofi collaboration revenue level.
• ~28 February 2027, est.: FDA target date for odronextamab in relapsed or refractory diffuse large B-cell lymphoma.

What would change the view

The case breaks if Q4 2026 Sanofi collaboration revenue, excluding the $1.0 billion upfront, falls below Q3's $2.724 billion. That would show the Q3 profit level was not repeatable. U.S. EYLEA HD sales flat or down from $699 million in the same report would remove the second growth source.

An FDA complete response letter for cemdisiran in November 2026 would remove the nearest new launch and end the case as written. A second syringe rejection would weaken the Q4 EYLEA HD demand guidance.

On price, a daily close below $850 ends the thesis. That level sits under Morgan Stanley's $855 target and well under the $927.89 report-day close.

The case would strengthen with a cemdisiran approval, followed by Q4 collaboration revenue above $2.724 billion excluding the upfront.

What it trades with

MarketBeat listed a beta of 0.10 on 5 November 2026, so the shares have moved little with the broad market, and company and health-care sector events drive them more. Sanofi's results read across directly because Sanofi records worldwide Dupixent sales. Retina competition links the shares to rival eye-drug launches, and the nex-z program ties a small part of the pipeline story to Intellia's trial news.